4087 resources
By Version
By Authority
Package | Version | Identity | Name/Title | Status | Date | Auth | Source(s) |
---|---|---|---|---|---|---|---|
hl7.fhir.uv.pharm-quality | R5 | vs-equipmentClass-pq | Equipment Classes | active | 2024-05 | hl7 | tho |
hl7.fhir.uv.pharm-quality | R5 | vs-goalPriority-pq | Goal Priority | active | 2024-05 | hl7 | fhir |
hl7.fhir.uv.pharm-quality | R5 | vs-grade-pq | Grades | active | 2024-05 | hl7 | tho |
hl7.fhir.uv.pharm-quality | R5 | vs-impurity-origin-pq | Impurity Origins | active | 2024-05 | hl7 | tho |
hl7.fhir.uv.pharm-quality | R5 | vs-impurity-type-pq | Impurity Types | active | 2024-05 | hl7 | tho |
hl7.fhir.uv.pharm-quality | R5 | vs-ingredientFunction-pq | Ingredient Function | active | 2024-05 | hl7 | tho |
hl7.fhir.uv.pharm-quality | R5 | vs-manufactured-item-property-pq | Manufactured Item Property | active | 2024-05 | hl7 | fhir |
hl7.fhir.uv.pharm-quality | R5 | vs-manufacturingParticipantRole-pq | Manufacturing Participant Role | active | 2024-05 | hl7 | tho |
hl7.fhir.uv.pharm-quality | R5 | vs-manufacturingStep-pq | Manufacturing Step | active | 2024-05 | hl7 | tho |
hl7.fhir.uv.pharm-quality | R5 | vs-manufacturingStepScale-pq | Manufacturing Step Scale | active | 2024-05 | hl7 | tho |
hl7.fhir.uv.pharm-quality | R5 | vs-medicinalproduct-characteristic-type | MedicinalProduct Characteristic Type | active | 2024-05 | hl7 | fhir |
hl7.fhir.uv.pharm-quality | R5 | vs-medicine-doseform | Medicine Dose Form EDQM | active | 2024-05 | hl7 | |
hl7.fhir.uv.pharm-quality | R5 | vs-medicine-route-of-administration | Medicine Route of Administration EDQM | active | 2024-05 | hl7 | |
hl7.fhir.uv.pharm-quality | R5 | vs-packageProperty-pq | Package Property | active | 2024-05 | hl7 | tho |
hl7.fhir.uv.pharm-quality | R5 | vs-pharmaceutical-organization-type | Pharmaceutical Organization Type | active | 2024-05 | hl7 | tho |
hl7.fhir.uv.pharm-quality | R5 | vs-planType-pq | Plan Type | active | 2024-05 | hl7 | tho |
hl7.fhir.uv.pharm-quality | R5 | vs-process-validation-procedure-pq | Process Validation Procedure | active | 2024-05 | hl7 | fhir |
hl7.fhir.uv.pharm-quality | R5 | vs-processParameter-pq | Process Parameter | active | 2024-05 | hl7 | tho |
hl7.fhir.uv.pharm-quality | R5 | vs-productNameType-pq | Product Name Type | active | 2024-05 | hl7 | fhir |
hl7.fhir.uv.pharm-quality | R5 | vs-productSiteUtilizationType-pq | Product Site Utilization | active | 2024-05 | hl7 | tho |
hl7.fhir.uv.pharm-quality | R5 | vs-qualifiedValueCriticality-pq | Qualified Value Criticality | active | 2024-05 | hl7 | tho |
hl7.fhir.uv.pharm-quality | R5 | vs-reportType-pq | Report Type | active | 2024-05 | hl7 | tho |
hl7.fhir.uv.pharm-quality | R5 | vs-specification-type-pq | Specification Type | active | 2024-05 | hl7 | fhir |
hl7.fhir.uv.pharm-quality | R5 | vs-substance-property-pq | Substance Property | active | 2024-05 | hl7 | fhir |
hl7.fhir.uv.pharm-quality | R5 | vs-substance-property-value-pq | Substance Property Value | active | 2024-05 | hl7 | fhir |
hl7.fhir.uv.pharm-quality | R5 | vs-test-method-pq | Test Method | active | 2024-05 | hl7 | fhir |
hl7.fhir.uv.pharm-quality | R5 | vs-testCategory-pq | Test Category | active | 2024-05 | hl7 | tho |
hl7.fhir.uv.pharm-quality | R5 | vs-timePointDescription-pq | Time Point Description | active | 2024-05 | hl7 | tho |
hl7.fhir.uv.order-catalog | R5 | bibliography-artifact-type | Types of bibliographic artifacts | active | 2019-12 | hl7 | fhir |
hl7.fhir.uv.order-catalog | R5 | catalog-message-events-vs | Message event codes for exchanging order catalog content | active | 2020-04 | hl7 | fhir |
hl7.fhir.uv.order-catalog | R5 | example-clinical-focus | All possible clinical contexts for any lab test | active | 2019-12 | hl7 | sct |
hl7.fhir.uv.order-catalog | R5 | example-normal-contexts-vitamin-d | Contextes de remboursement du dosage de la vitamine D | active | 2019-12 | hl7 | sct |
hl7.fhir.uv.order-catalog | R5 | example-reasons-for-order | All Valid Reasons for Ordering a Lab Service | active | 2019-12 | hl7 | sct |
hl7.fhir.uv.order-catalog | R5 | laboratory-service-reimbursability-vs | Kinds of reibursability coarse categories for a laboratory service | active | 2020-03 | hl7 | fhir |
hl7.fhir.uv.order-catalog | R5 | laboratory-service-type | Types of diagnostic services performed by a laboratory | active | 2019-12 | hl7 | fhir |
hl7.fhir.uv.vulcan-rwd | R4 | ExampleACSConditionCodes | ACS Example Condition Codes | active | 2023-05 | hl7 | icd |
hl7.fhir.uv.vulcan-rwd | R4 | ExampleACSOralAntiplatelets | ACS Example Oral Antiplatelet Drug Codes | active | 2023-05 | hl7 | fhir |
hl7.fhir.uv.vulcan-rwd | R4 | ExampleAntiTNFADrugCodes | AntiTNFA Example Drug Codes | active | 2023-05 | hl7 | example |
hl7.fhir.uv.vulcan-rwd | R4 | ExampleCOVID19TestCodes | Covid-19 Example Test Codes | active | 2023-05 | hl7 | loinc |
hl7.fhir.uv.vulcan-rwd | R4 | ExampleClopidogrelCodes | ACS Example Clopidogrel Codes | active | 2023-05 | hl7 | rx ndc |
hl7.fhir.uv.vulcan-rwd | R4 | ExampleCrohnsDiseaseConditionCodes | AntiTNFA Example Condition Codes | active | 2023-05 | hl7 | icd |
hl7.fhir.uv.vulcan-rwd | R4 | ExampleDiabetesConditionCodes | Diabetes Example Condition Codes | active | 2023-05 | hl7 | icd |
hl7.fhir.uv.vulcan-rwd | R4 | ExampleDialysisProcedureCodes | Diabetes Example Dialysis Test Codes | active | 2023-05 | hl7 | sct |
hl7.fhir.uv.vulcan-rwd | R4 | ExampleHbA1cTestCodes | Diabetes Example Test Codes | active | 2023-05 | hl7 | loinc |
hl7.fhir.uv.vulcan-rwd | R4 | ExampleNonBNT162b2Codes | Covid-19 Example Vaccine Codes | active | 2023-05 | hl7 | cvx |
hl7.fhir.uv.vulcan-rwd | R4 | ExamplePrasugrelCodes | ACS Example Prasugrel Codes | active | 2023-05 | hl7 | rx ndc |
hl7.fhir.uv.vulcan-rwd | R4 | ExampleRespiratoryConditionCodes | Covid-19 Example Condition Codes | active | 2023-05 | hl7 | sct icd |
hl7.fhir.uv.vulcan-rwd | R4 | ExampleTicagrelorCodes | ACS Example Ticagrelor Codes | active | 2023-05 | hl7 | rx ndc |
hl7.fhir.uv.cmi | R4 | cql-version | CQL Version | active | 2021-08 | hl7 | fhir |
hl7.fhir.uv.cmi | R4 | value-filter-comparator | Value Filter Comparator | active | 2021-08 | hl7 | fhir |
hl7.fhir.uv.cpg.antenatalcare | R4 | anc-reason-for-visit-vs | ValueSet - ANC Reason for Visit | active | 2024-08 | hl7 | fhir |
ihe.iti.mhd | R4 | DocumentReferenceStats | MHD DocumentReference status codes | active | 2024-07 | ihe | fhir |
ihe.iti.mhd | R4 | MHDlistTypesVS | MHD List Types ValueSet | active | 2024-07 | ihe | ihe |
ihe.iti.mhd | R4 | MHDprovideFolderActions | MHD Folder List Types ValueSet | active | 2024-07 | ihe | fhir |
ihe.iti.mhd | R4 | MHDprovidePatientActions | MHD Patient Types ValueSet | active | 2024-07 | ihe | fhir |
hl7.fhir.uv.cpg | R4 | anc-reason-for-visit-vs | ANC Reason for Visit ValueSet | active | 2024-10 | hl7 | fhir |
hl7.fhir.uv.cpg | R4 | cpg-active-condition-vs | CPG Active Condition Value Set | active | 2024-10 | hl7 | tho |
hl7.fhir.uv.cpg | R4 | cpg-activity-type-vs | CPG Activity Type Value Set | active | 2024-10 | hl7 | fhir |
hl7.fhir.uv.cpg | R4 | cpg-casefeature-pertinence-vs | CPG Case Feature Pertinence Value Set | active | 2024-10 | hl7 | fhir |
hl7.fhir.uv.cpg | R4 | cpg-casefeature-type-vs | CPG Case Feature Type Value Set | active | 2024-10 | hl7 | fhir |
hl7.fhir.uv.cpg | R4 | cpg-common-persona-vs | CPG Common Persona Value Set | active | 2024-10 | hl7 | fhir |
hl7.fhir.uv.cpg | R4 | cpg-common-process-vs | CPG Common Process Value Set | active | 2024-10 | hl7 | fhir |
hl7.fhir.uv.cpg | R4 | cpg-recommendation-direction-vs | CPG Recommendation Direction Value Set | active | 2024-10 | hl7 | fhir |
hl7.fhir.uv.cpg | R4 | http://hl7.org/fhir/ValueSet/knowledge-capability | Knowledge Capability Values | active | 2019-07 | hl7 | fhir |
hl7.fhir.uv.cpg | R4 | http://hl7.org/fhir/ValueSet/knowledge-representation-level | Knowledge Representation Level Values | active | 2019-07 | hl7 | fhir |
ihe.domain.profile | R4 | ihe-ToDo-laughing-positions | The positions during laughing | draft | 2024-07 | ihe | loinc |
hl7.fhir.uv.phd | R4B | ASN1attribute | ANS1ToHL7 codes defined for non-measurement attributes | active | 2018-09 | hl7 | fhir |
hl7.fhir.uv.phd | R4B | ASN1measurement | ANS1ToHL7 codes defined for measurement attributes | active | 2018-09 | hl7 | fhir |
hl7.fhir.uv.phd | R4B | CodeableConcept11073MDC | CodeableConcept 11073 Attributes | active | 2018-11 | hl7 | iso |
hl7.fhir.uv.phd | R4B | DeviceSystemIdIdentifier | Device System Id Identifier | active | 2018-11 | hl7 | fhir |
hl7.fhir.uv.phd | R4B | DeviceTransportIdentifiers | Device Transport Address Identifiers | active | 2018-11 | hl7 | fhir |
hl7.fhir.uv.phd | R4B | DeviceTypes11073MDC | Device Type Specialization IEEE 11073-10101 Nomenclature Codes | active | 2021-09 | hl7 | iso |
hl7.fhir.uv.phd | R4B | MDCnotObject | 11073 MDC Non-Object codes | active | 2024-10 | hl7 | iso |
hl7.fhir.uv.phd | R4B | MDCobject | IEEE 11073 MDC Object infrastructure and Device nomenclature | active | 2024-10 | hl7 | iso |
hl7.fhir.uv.phd | R4B | Quantity11073MDC | Quantity 11073 Attributes | active | 2018-11 | hl7 | iso |
hl7.fhir.uv.phd | R4B | Range11073MDC | Range 11073 Attributes | active | 2018-11 | hl7 | iso |
hl7.fhir.uv.phd | R4B | String11073MDC | String 11073 Attributes | active | 2018-11 | hl7 | iso |
hl7.fhir.uv.pddi | R4 | valueset-AAS | Aldosterone Antagonists Drug Value Set | draft | 2018-07 | hl7 | fhir |
hl7.fhir.uv.pddi | R4 | valueset-CYCS | Composite Cyclosporine Drug Value Set | draft | 2018-07 | hl7 | fhir |
hl7.fhir.uv.pddi | R4 | valueset-Hx-UGIB-snomed | Upper gastrointestinal bleed Value Set | draft | 2018-06 | hl7 | sct |
hl7.fhir.uv.pddi | R4 | valueset-LOOPDIURETIC | Loop Diuretic Drug Value Set | draft | 2018-08 | hl7 | fhir |
hl7.fhir.uv.pddi | R4 | valueset-NSAIDS | Nonsteroidal Anti-inflammatory Drugs Value Set | draft | 2018-07 | hl7 | fhir |
hl7.fhir.uv.pddi | R4 | valueset-PDDICDS-indicator | PDDI CDS indicator | active | 2024-02 | hl7 | fhir |
hl7.fhir.uv.pddi | R4 | valueset-PPIS | Proton Pump Inhibitor Drug Value Set | draft | 2018-06 | hl7 | fhir |
hl7.fhir.uv.pddi | R4 | valueset-SCS | Systemic Corticosteroid Drug Value Set | draft | 2018-07 | hl7 | fhir |
hl7.fhir.uv.pddi | R4 | valueset-aldosterone | Aldosterone Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-aspirin | Aspirin Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-betamethasone-exclude | Exclude Betamethasone Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-betamethasone | Betamethasone Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-bromfenac-exclude | Exclude Bromfenac Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-bromfenac | Bromfenac Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-bumetanide | Bumetanide Medications Value Set | draft | 2022-11 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-calcium-LOINC | LOINC Codes for Serum Calcium | draft | 2018-08 | hl7 | loinc |
hl7.fhir.uv.pddi | R4 | valueset-celecoxib | Celecoxib Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-cloprednol | Cloprednol Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-cortisone | Cortisone Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-cortivazol | Cortivazol Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-cyclosporine-exclude | Exclude cyclosporine Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-cyclosporine | Cyclosporine Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-deflazacort | Deflazacort Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-desoxycorticosterone | Desoxycorticosterone Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-dexamethasone-exclude | Exclude Dexamethasone Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-dexamethasone | Dexamethasone Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-dexlansoprazole | Dexlansoprazole Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-diclofenac-exclude | Exclude Diclofenac Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-diclofenac | Diclofenac Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-diflunisal | Diflunisal Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-digoxin-LOINC | LOINC Codes for Digoxin Concentration | draft | 2018-08 | hl7 | loinc |
hl7.fhir.uv.pddi | R4 | valueset-digoxin | Digoxin Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-eplerenone | Eplerenone Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-esomeprazole | Esomeprazole Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-ethacrynate | Ethacrynate Medications Value Set | draft | 2022-11 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-etodolac | Etodolac Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-fenoprofen | Fenoprofen Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-fludrocortisone | Fludrocortisone Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-fluocortolone-exclude | Exclude Fluocortolone Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-fluocortolone | Fluocortolone Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-flurbiprofen-exclude | Exclude Flurbiprofen Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-flurbiprofen | Flurbiprofen Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-furosemide | Furosemide Medications Value Set | draft | 2022-11 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-hydrocortisone-exclude | Exclude Hydrocortisone Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-hydrocortisone | Hydrocortisone Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-ibuprofen-exclude | Exclude Ibuprofen Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-ibuprofen | Ibuprofen Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-indomethacin | Indomethacin Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-ketoprofen-exclude | Exclude Ketoprofen Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-ketoprofen | Ketoprofen Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-ketorolac-exclude | Exclude Ketorolac Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-ketorolac | Ketorolac Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-lansoprazole | Lansoprazole Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-magnesium-LOINC | LOINC Codes for Serum Potassium | draft | 2018-08 | hl7 | loinc |
hl7.fhir.uv.pddi | R4 | valueset-mefenamate | Mefenamate Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-meloxicam | Meloxicam Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-meprednisone | Meprednisone Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-methylprednisolone-exclude | Exclude Methylprednisolone Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-methylprednisolone | Methylprednisolone Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-misoprostol | Misoprostol Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-nabumetone | Nabumetone Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-naproxen | Naproxen Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-nepafenac-exclude | Exclude Nepafenac Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-nepafenac | Nepafenac Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-omeprazole | Omeprazole Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-oxaprozin | Oxaprozin Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-pantoprazole | Pantoprazole Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-paramethasone | Paramethasone Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-piroxicam-exclude | Exclude Piroxicam Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-piroxicam | Piroxicam Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-potassium-LOINC | LOINC Codes for Serum Potassium | draft | 2018-08 | hl7 | loinc |
hl7.fhir.uv.pddi | R4 | valueset-prednisolone-exclude | Exclude Prednisolone Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-prednisolone | Prednisolone Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-prednisone | Prednisone Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-prednylidene | Prednylidene Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-rabeprazole | Rabeprazole Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-renal-LOINC | LOINC Codes for Renal Function | draft | 2018-08 | hl7 | loinc |
hl7.fhir.uv.pddi | R4 | valueset-rimexolone-exclude | Exclude Rimexolone Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-rimexolone | Rimexolone Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-spironolactone | Spironolactone Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-sulindac | Sulindac Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-tolmetin | Tolmetin Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-topicaldiclofenac | Topical Diclofenac Medications Value Set | draft | 2022-11 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-torsemide | Torsemide Medications Value Set | draft | 2022-11 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-triamcinolone-exclude | Exclude Triamcinolone Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-triamcinolone | Triamcinolone Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-trilostane | Trilostane Medications Value Set | draft | 2018-07 | hl7 | rx |
hl7.fhir.uv.pddi | R4 | valueset-warfarin | Warfarin Medications Value Set | draft | 2018-07 | hl7 | rx |
ihe.pcc.aps | R4 | Advance.Directives.VS | Advance Directives | draft | 2023-10 | ihe | sct |
ihe.pcc.aps | R4 | Alcohol.USe.Frequency.VS | Alcohol USe Frequency | draft | 2023-10 | ihe | ucum |
ihe.pcc.aps | R4 | Antepartum.Education.VS | Antepartum Education | draft | 2023-10 | ihe | sct |
ihe.pcc.aps | R4 | Antepartum.Family.History.and.Genetic.Screening.VS | Antepartum Family History and Genetic Screening | draft | 2023-10 | ihe | sct |
ihe.pcc.aps | R4 | Antepartum.History.of.Infection.VS | Antepartum History of Infection | draft | 2023-10 | ihe | sct |
ihe.pcc.aps | R4 | Antepartum.History.of.Past.Illness.VS | Antepartum History of Past Illness | draft | 2023-10 | ihe | sct |
ihe.pcc.aps | R4 | Antepartum.Laboratory.VS | Antepartum Laboratory | draft | 2023-10 | ihe | loinc |
ihe.pcc.aps | R4 | Antepartum.Review.of.Systems.Menstrual.History.VS | Antepartum Review of Systems Menstrual History | draft | 2023-10 | ihe | sct |
ihe.pcc.aps | R4 | Smoking.Status.VS | Smoking Status | draft | 2023-10 | ihe | sct |
ihe.pcc.aps | R4 | Smoking.Tabbacco.Use.Frequency.VS | Smoking Tabbacco Use Frequency | draft | 2023-10 | ihe | ucum |
hl7.fhir.uv.cpg.opioids | R4 | opioids-with-ambulatory-abuse-potential | Opioids with Ambulatory Abuse Potential | active | 2024-08 | hl7 | rx |
who.fhir.anc-cds | R4 | anc-a-de13 | Co-habitants | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-a-de14 | Co-habitants Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-activity-codes | ANC Activity Codes | active | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de1 | Counselling on Caffeine Reduction | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de10 | Counselling on Second-Hand Smoke | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de102 | Type of vitamin A supplement dosage provided Choices | draft | 2024-09 | who | ucum |
who.fhir.anc-cds | R4 | anc-b10-de104 | Vitamin A supplementation not provided | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de105 | Vitamin A supplementation not provided Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de108 | Reason calcium not prescribed | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de109 | Reason calcium not prescribed Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de113 | Risk of pre-eclampsia | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de114 | Pre-eclampsia risk counselling provided | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de116 | Reason aspirin not prescribed | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de117 | Reason aspirin not prescribed Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de121 | Risk of gestational diabetes mellitus (GDM) | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de124 | Gestational diabetes mellitus (GDM) risk counselling conducted | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de125 | Counselling conducted on HIV risk | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de126 | PrEP for HIV prevention provided | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de127 | Reason PrEP for HIV prevention was not provided | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de128 | Reason PrEP for HIV prevention was not provided Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de13 | Counselling on Condom Use | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de133 | Counselling conducted on seeking care when danger signs occur | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de134 | Counsel to immediately go to the hospital if severe danger signs are present | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de135 | Counselling on ANC contact schedule conducted | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de136 | Counselling conducted on birth preparedness and complications readiness | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de137-choices-grouper | Planned birth place Choices Grouper | draft | 2021-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de137 | Planned birth place | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de138 | Planned birth place Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de14 | Counselling on Condom Use | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de140 | Planned birth place - Home Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de142 | Counselling conducted on Rh factor negative | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de143 | Counselling conducted on intrapartum antibiotic to prevent early neonatal Group B Streptococcus (GBS) infection | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de144 | Counselling on postpartum family planning conducted | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de145-choices-grouper | Family planning method selected Choices Grouper | draft | 2021-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de145 | Family planning method selected | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de146 | Family planning method selected - Copper-bearing intrauterine device (Cu-IUD) Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de147 | Family planning method selected - Levonorgestrel intrauterine device (LNG-IUD) Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de148 | Family planning method selected Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de162 | Family planning method selected - Female sterilization Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de164 | Counselling conducted on breastfeeding | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de165 | Tetanus toxoid (TT) 1 immunization provided | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de167 | Tetanus toxoid (TT) 2 immunization provided | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de169 | Tetanus toxoid (TT) 3 immunization provided | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de17 | Counselling on Alcohol Substance Abuse | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de171 | Tetanus toxoid (TT) 4 immunization provided | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de173 | Tetanus toxoid (TT) 5 immunization provided | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de175 | Reason tetanus toxoid (TT) vaccination not provided | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de176 | Reason tetanus toxoid (TT) vaccination not provided Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de18 | Counselling on Alcohol Substance Abuse | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de181 | Counselling conducted on Hep B negative | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de182 | Hepatitis B-1 immunization provided | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de184 | Hepatitis B-2 immunization provided | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de186 | Hepatitis B-3 immunization provided | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de188 | No doses of hepatitis B | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de189 | Reason Hep B vaccination not provided | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de190 | Reason Hep B vaccination not provided Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de195 | Flu immunization provided | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de197 | Reason flu vaccine not provided | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de198 | Reason flu vaccine not provided Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de2 | Counselling on Caffeine Reduction | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de203 | IPV first-line support provided | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de204 | Reason IPV first line support not done | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de205 | Reason IPV first line support not done Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de21 | Counselling on Non-Pharma Measures to Relieve Nausea and Vomiting | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de210 | What additional type of care provided | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de211 | What additional type of care provided Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de216 | Safety assessement | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de217 | Has the physical violence happened more often or gotten worse over the past 6 months | draft | 2024-09 | who | |
who.fhir.anc-cds | R4 | anc-b10-de218 | Has he ever used a weapon or threatened you with a weapon | draft | 2024-09 | who | |
who.fhir.anc-cds | R4 | anc-b10-de219 | Has he ever tried to strangle you | draft | 2024-09 | who | |
who.fhir.anc-cds | R4 | anc-b10-de22 | Counselling on Non-Pharma Measures to Relieve Nausea and Vomiting | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de220 | Has he ever beaten you when you were pregnant | draft | 2024-09 | who | |
who.fhir.anc-cds | R4 | anc-b10-de221 | Is he violently and constantly jealous of you | draft | 2024-09 | who | |
who.fhir.anc-cds | R4 | anc-b10-de222 | Do you believe he could kill you | draft | 2024-09 | who | |
who.fhir.anc-cds | R4 | anc-b10-de223 | Referrals made as part of first-line support and care | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de224 | Was client referred | draft | 2024-09 | who | |
who.fhir.anc-cds | R4 | anc-b10-de225 | Was client referred Choices | draft | 2024-09 | who | |
who.fhir.anc-cds | R4 | anc-b10-de233 | Preventive antihelminthic treatment provided | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de234 | Preventive antihelminthic treatment provided Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de237 | Reason no preventative treatment provided | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de238 | Reason no preventative treatment provided Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de241 | Counselling conducted on malaria prevention | draft | 2024-09 | who | |
who.fhir.anc-cds | R4 | anc-b10-de242 | Counselling conducted on malaria prevention | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de245 | IPTp-SP dose 1 provided | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de247 | IPTp-SP dose 2 provided | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de249 | IPTp-SP dose 3 provided | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de25 | Counselling on Pharmacological Measures to Relieve Nausea and Vomiting | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de251 | Malaria Prophylaxis | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de252 | Reason malaria prophylaxis not provided Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de256 | Referral to Hospital | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de257 | Referral to Hospital | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de258 | Reason referral not done Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de26 | Counselling on Pharmacological Measures to Relieve Nausea and Vomiting | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de29 | Counselling on Diet and Lifestyle Changes to Prevent and Relieve Heartburn | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de3 | Procedure Not Done Reason Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de30 | Counselling on Diet and Lifestyle Changes to Prevent and Relieve Heartburn | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de33 | Counselling on Antacid Preparations to Relieve Heartburn | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de34 | Counselling on Antacid Preparations to Relieve Heartburn | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de37 | Counselling on Non-Pharmacological Treatment for Relief of Leg Cramps | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de38 | Counselling on Non-Pharmacological Treatment for Relief of Leg Cramps | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de41 | Counselling on Use of Magnesium-and Calcium to Relieve Leg Cramps | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de42 | Counselling on Use of Magnesium-and Calcium to Relieve Leg Cramps | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de45 | Counselling on Dietary Modifications to Relieve Constipation | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de46 | Counselling on Dietary Modifications to Relieve Constipation | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de49 | Counselling on Use of Wheat Bran or Other Fibre Supplements to Relieve Constipation | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de5 | Counselling on Tobacco Cessation | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de50 | Counselling on Use of Wheat Bran or Other Fibre Supplements to Relieve Constipation | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de53 | Counselling on Regular Exercise Physiotherapy Support Belts and Acupuncture to Relieve Low Back and Pelvic Pain | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de54 | Counselling on Regular Exercise Physiotherapy Support Belts and Acupuncture to Relieve Low Back and Pelvic Pain | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de57 | Counselling on Non-Pharmacological Options for Varicose Veins and Oedema | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de58 | Counselling on Non-Pharmacological Options for Varicose Veins and Oedema | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de6 | Counselling on Tobacco Cessation | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de61 | Counselling on Healthy Eating and Keeping Physically Active | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de62 | Counselling on Healthy Eating and Keeping Physically Active | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de65 | Counselling on Increasing Daily Energy Protein Intake | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de66 | Counselling on Increasing Daily Energy Protein Intake | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de69 | Counselling on Balanced Energy and Protein Dietary Supplementation | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de70 | Counselling on Balanced Energy and Protein Dietary Supplementation | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de73 | Hypertension | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de74 | Severe hypertension | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de75 | Pre-eclampsia | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de76 | Severe pre-eclampsia | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de77 | Counselling conducted on hypertension | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de78 | Counselling conducted on HIV positive | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de79 | Counselling conducted on hepatitis B positive | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de80 | Counselling conducted on hepatitis C positive | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de81 | Syphilis counselling and treatment | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de82 | Syphilis counselling, treatment and further testing | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de83 | Seven-day antibiotic regimen for asymptomatic bacteriuria (ASB) provided | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de84 | Reason seven-day antibiotic regimen for asymptomatic bacteriuria (ASB) not provided | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de85 | Reason seven-day antibiotic regimen for asymptomatic bacteriuria (ASB) not provided Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de87 | Counselling conducted on TB screening positive | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de88 | Counselling conducted on gestational diabetes mellitus (GDM) | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de89 | Counselling conducted on diabetes mellitus (DM) | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de9 | Counselling on Second-Hand Smoke | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de93 | Type of iron supplement dosage provided Choices | draft | 2024-09 | who | ucum |
who.fhir.anc-cds | R4 | anc-b10-de96 | Reason iron and folic acid not prescribed | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b10-de97 | Reason iron and folic acid not prescribed Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b4-de1 | Pregnancy confirmed | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b5-de1-choices-grouper | Reason for coming to facility Choices Grouper | draft | 2021-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b5-de1 | Reason for coming to facility | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b5-de2 | First Antenatal Care Contact Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b5-de3 | Scheduled Antenatal Care Contact Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b5-de4 | Reason for coming to facility Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b5-de48-choices-grouper | Danger signs Choices Grouper | draft | 2021-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b5-de48 | Danger signs | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b5-de49 | Danger Signs - No danger signs Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b5-de5 | Specific health concern(s) | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b5-de50 | Danger signs Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b5-de51 | Danger Signs - Central cyanosis Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b5-de6 | Specific health concern(s) Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de1 | Highest level of education achieved | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de100-choices-grouper | Tetanus toxoid-containing vaccine (TTCV) immunization history Choices Grouper | draft | 2021-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de100 | Tetanus toxoid-containing vaccine (TTCV) immunization history | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de101 | Tetanus toxoid-containing vaccine (TTCV) immunization history - Fully Immunized Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de102 | Tetanus toxoid-containing vaccine (TTCV) immunization history - Under Immunized Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de103 | Tetanus toxoid-containing vaccine (TTCV) immunization history - No Doses Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de104 | Tetanus toxoid-containing vaccine (TTCV) immunization history - Unknown Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de105-choices-grouper | Flu immunization history Choices Grouper | draft | 2021-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de105 | Flu immunization history | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de106 | Flu Immunization History - Fully Immunized Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de107 | Flu Immunization History - No Doses Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de108 | Flu Immunization History - Unknown Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de109-choices-grouper | Current medications Choices Grouper | draft | 2021-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de109 | Current medications | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de11 | Occupation - Employment that puts woman at increased risk for HIV (e.g. sex worker) Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de110 | Current medications Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de12 | Occupation - Informal employment (other) Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de125 | Current Medications - Co-trimoxazole Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de139-choices-grouper | Daily caffeine intake Choices Grouper | draft | 2021-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de139 | Daily caffeine intake | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de14 | Last menstrual period (LMP) date | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de140 | Daily caffeine intake - More than 2 cups of coffee Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de141 | Daily caffeine intake - More than 4 cups of tea Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de142 | Daily caffeine intake - More than 12 bars of chocolate Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de143 | Daily caffeine intake - More than one can of soda or energy drink Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de144 | Daily caffeine intake - None of the above daily caffeine intake Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de145 | Clinical enquiry for alcohol and other substance use done | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de146-choices-grouper | Current alcohol and/or other substance use Choices Grouper | draft | 2021-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de146 | Current alcohol and/or other substance use | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de147 | Current alcohol and/or other substance use - None Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de148 | Current alcohol and/or other substance use - Alcohol Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de149 | Current alcohol and/or other substance use - Cocaine Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de15 | Ultrasound done | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de150 | Current alcohol and/or other substance use - Injectable drugs Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de151 | Current alcohol and/or other substance use - Marijuana Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de152 | Current alcohol and/or other substance use - Other (specify) Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de153 | Tobacco use | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de154 | Recently quit tobacco products | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de155 | Exposure to second-hand smoke | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de156-choices-grouper | Partner HIV status (reported) Choices Grouper | draft | 2021-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de156 | Partner HIV status (reported) | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de157 | Partner HIV status (reported) - HIV Positive Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de158 | Partner HIV status (reported) - HIV Negative Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de159 | Partner HIV status (reported) - Inconclusive Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de160 | Contraceptive use of male condoms | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de161 | Contraceptive use of female condoms | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de17 | Gestational age | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de18 | Source of gestational age | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de19 | Source of gestational age Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de2 | Highest level of education achieved Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de22 | Expected date of delivery (EDD) | draft | 2024-09 | who | |
who.fhir.anc-cds | R4 | anc-b6-de24 | Number of pregnancies (gravida) | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de25 | Number of miscarriages and/or abortions | draft | 2024-09 | who | |
who.fhir.anc-cds | R4 | anc-b6-de26 | Number of live births | draft | 2024-09 | who | |
who.fhir.anc-cds | R4 | anc-b6-de27 | Whether last live birth was preterm | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de28 | Whether last live birth was preterm Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de31 | Number of stillbirths | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de32 | Parity | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de33 | Number of caesarian sections | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de34-choices-grouper | Past pregnancy complications Choices Grouper | draft | 2021-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de34 | Past pregnancy complications | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de35 | Past pregnancy complications Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de37 | Past pregnancy complications - Pre-eclampsia Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de38 | Past pregnancy complications - Eclampsia Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de41 | Past pregnancy complications - Convulsions Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de42 | Past pregnancy complications - Forceps Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de43 | Past pregnancy complications - Gestational diabetes mellitus Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de44 | Past pregnancy complications - Heavy bleeding (during or after delivery) Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de45 | Past pregnancy complications - Macrosomia Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de46 | Past pregnancy complications - Perineal tear (3rd or 4th degree) Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de51 | Substance use during past pregnancy specification | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de53 | Substance use during past pregnancy specification Choices | draft | 2024-09 | who | internal |
who.fhir.anc-cds | R4 | anc-b6-de57 | Allergies | draft | 2024-09 | who | internal |
XIG built as of 17 Oct 2024. Found 40652 resources in 683 packages.